更新于：2024-11-04
Flumatinib Mesylate
甲磺酸氟马替尼
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 Flumatinib mesylate - Jiangsu Hansoh Pharmaceutical、HH-GV-678、HH-GV678 + [3] |
靶点 |
作用机制 Bcr-Abl抑制剂(bcr-abl酪氨酸激酶抑制剂) |
在研适应症 |
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2019-11-22), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构
分子式C30H33F3N8O4S |
InChIKeyZSASDYCFROUKTJ-UHFFFAOYSA-N |
CAS号895519-91-2 |
关联
28
项与 甲磺酸氟马替尼 相关的临床试验A Phase Ⅱ, Open Label, Single Arm, Single-Center Study to Evaluate the Efficacy and Safety of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
Evaluating the Efficacy and Safety of Flumatinib Versus Imatinib for in Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML)-in Chronic Phase (CP): A Multicenter, Open-label, Real World Study
多中心、随机、双盲研究，评估甲磺酸氟马替尼片 400mg 与 600mg 在 新诊断慢性髓性白血病慢性期受试者中的有效性和安全性
100 项与 甲磺酸氟马替尼 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸氟马替尼 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸氟马替尼 相关的专利（医药）
登录后查看更多信息
47
项与 甲磺酸氟马替尼 相关的文献（医药）2024-09-01Heliyon
Chronic myeloid leukemia during osimertinib treatment in a non-small cell lung cancer patient: A case report
Article
作者: Zhang, Libo ; Huang, Meijuan
Case summary:
A 45-year-old man presented with a 4.0cm × 4.0cm mass in right lower lobe and a right lower lobectomy was performed. The pathological diagnosis from the right lower lobe mass was adenocarcinoma with an EGFR mutation in exon 21 (L858R). He chose osimertinib as postoperative adjuvant treatment. Eight months after the administration of osimertinib, leukocytosis was detected and we diagnosed the patient with chronic myeloid leukemia (CML). After the diagnosis was made, the patient started the treatment of flumatinib immediately, and treatment of osimertinib continued. After one month treatment, leukocytosis was completely relived. The patient was receiving treatment of osimertinib and flumatinib simultaneously with both lung cancer and leukemia well-controlled, and the side effects were tolerable.
Conclusion:
Hemogram of non-small cell lung cancer (NSCLC) patients should be carefully monitored during EGFR-TKIs treatment. While there is a potential association between EGFR-TKIs and the development of hematologic abnormalities such as CML, more evidence is needed to clarify whether EGFR-TKIs have a leukemogenic effect. For patients with CML during EGFR-TKIs treatment, osimertinib combined with flumatinib may be an effective treatment modalities and the side effects can be tolerated.
2024-09-01ANNALS OF HEMATOLOGY
ETV6::ABL1 positive myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) with blast crisis treated with flumatinib mesylate
Article
作者: Chen, Fei
ETV6::ABL1 fusion gene is a rare but recurrent genomic rearrangement in hematological malignancies with poor prognosis. Here, we report 1 case of Ph negative myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) who carry ETV6::ABL1 fusion gene. The patient achieved clinical remission after treatment with imatinib. However, disease progression of blast crisis was observed around 2 years later. The patient was treated with second-generation tyrosine kinase inhibitor of flumatinib, yielded a short term second therapeutic response. ETV6::ABL1 positive myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) is rare and may be misdiagnosed by conventional cytogenetical analysis. Early treatment with TKIs, particularly second-generation TKIs, may be beneficial to improve treatment results.
2024-08-01MOLECULAR CARCINOGENESIS
Atypical BCR‐ABL1 transcript in mixed phenotype acute leukemia with bone marrow necrosis
Article
作者: Liu, Xin ; Yuan, Dai ; Xu, Hongzhi ; Zhao, Wenbo ; Liu, Jiarui ; Zhang, Zhifen ; Jiang, Yujie
Abstract:
Mixed phenotype acute leukemia (MPAL) is a type of acute leukemia in which encompasses mixed features of myeloid, T‐lymphoid, and/or B‐lymphoid differentiation. Philadelphia chromosome‐positive (Ph+) MPAL is a rare subgroup with a poor prognosis and accounts for ＜1% of adult acute leukemia. Until now, there is still no consensus on how to best treat Ph+ MPAL. Here, we report a 62‐year‐old male with Ph+ (atypical e13a2 BCR‐ABL1 fusion protein) MPAL. This patient presented with recurrent and intense bone pain due to bone marrow necrosis (BMN). Besides, he did not achieve a complete remission for the first two chemotherapies, until he received flumatinib combined with hyper‐CVAD (B) (a dose‐intensive regimen include methotrexate and cytarabine). To our knowledge, this is the first report to describe the coexistence of BMN and atypical e13a2 BCR‐ABL1 transcripts in patients with MPAL. This finding will bring new understandings in the diagnosis and treatment of Ph+ MPAL.
100 项与 甲磺酸氟马替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性期慢性髓性白血病 | 中国 | 2019-11-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 费城染色体阳性慢性粒细胞白血病 | 临床3期 | 中国 | 2014-08-26 | |
| 急性转化期慢性粒细胞性白血病 | 临床2期 | 中国 | 2013-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
ESMO2024 人工标引  | N/A | 48 | Flumatinib combined with multiagent chemotherapy | 齋襯蓋鏇願遞構選窪築(鬱選築壓醖鹽齋遞願窪) = 簾壓鏇壓鹽廠餘蓋廠衊 願鹹製選蓋憲構淵顧蓋 (餘糧衊觸選鏇窪壓膚顧 ) 更多 | 积极 | 2024-09-15 | |
N/A | 94 | 襯鹽選艱襯築觸遞蓋網(衊選遞鹽窪鑰艱醖遞構) = 獵蓋壓遞齋壓製艱顧艱 積廠製膚廠膚選齋築獵 (膚簾鑰繭構憲糧鑰廠廠 ) 更多 | - | 2023-12-10 | |||
临床2期 | 63 | Flumatinib + VIP-based chemotherapy regimen | 餘顧製鏇繭顧蓋鏇獵鹽(觸醖糧壓範鑰積選壓蓋) = 網構壓淵襯醖鑰醖鹽構 淵餘壓夢夢糧艱選觸簾 (艱壓憲顧鏇簾蓋獵蓋鹹 ) 更多 | - | 2023-06-08 | ||
N/A | - | 壓餘願襯衊觸構憲構選(網蓋顧繭遞遞鹽顧鬱構) = 簾願蓋壓膚糧繭網淵範 壓觸遞衊鹽獵構積獵獵 (膚繭衊壓鬱齋願鏇顧夢 ) | - | 2022-06-10 | |||
壓餘願襯衊觸構憲構選(網蓋顧繭遞遞鹽顧鬱構) = 壓鏇壓鬱觸鏇齋壓範壓 壓觸遞衊鹽獵構積獵獵 (膚繭衊壓鬱齋願鏇顧夢 ) | |||||||
临床3期 | 394 | 網鏇齋膚簾範鑰鹹簾積(窪願蓋艱獵鹹夢製構醖) = 餘選觸觸廠壓繭簾夢憲 鑰艱鏇壓願糧艱鹽鹹簾 (艱鹹襯製選繭鏇鏇窪鏇 ) 更多 | 优效 | 2021-01-01 | |||
網鏇齋膚簾範鑰鹹簾積(窪願蓋艱獵鹹夢製構醖) = 蓋遞範壓製觸選壓製鹹 鑰艱鏇壓願糧艱鹽鹹簾 (艱鹹襯製選繭鏇鏇窪鏇 ) 更多 | |||||||
临床3期 | 400 | 膚夢觸願範艱醖艱廠壓(製製廠遞蓋繭築構鬱糧) = 獵淵顧積積壓鬱鏇簾構 顧獵製製膚窪憲餘窪網 (遞遞衊觸繭顧遞鹹鹹鬱, 27.06 ~ 40.29) 更多 | 积极 | 2019-05-26 | |||
膚夢觸願範艱醖艱廠壓(製製廠遞蓋繭築構鬱糧) = 衊衊膚遞襯鏇範製範積 顧獵製製膚窪憲餘窪網 (遞遞衊觸繭顧遞鹹鹹鬱, 12.88 ~ 23.67) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用